Literature DB >> 34405689

Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV and Aging Workshop.

Asante R Kamkwalala1, Ankita Garg2, Upal Roy3, Avery Matthews4, Jose Castillo-Mancilla5, Jordan E Lake6, Giada Sebastiani7, Michael Yin8, Todd T Brown9, Angela R Kamer10, Douglas A Jabs11,12, Ronald J Ellis13,14, Marta Boffito15, Meredith Greene16, Sarah Schmalzle17, Eugenia Siegler18, Kristine M Erlandson5, David J Moore14.   

Abstract

The number of people with HIV (PWH) aged 50 years or older continues to steadily increase. The convergence of age- and HIV-related complications in these individuals presents a challenge for both patients and clinicians alike. New findings continue to emerge, as numerous researchers evaluate the combined impact of these two factors on quality of life, physiological systems, and mental health in PWH. Since its first occurrence in 2009, the International Workshop on HIV and Aging has served as a multidisciplinary meeting to share basic biomedical data, clinical trial results, treatment strategies, and epidemiological recommendations, toward better understanding and outcomes among like-minded scientific professionals. In this article, we share a selection of key findings presented in plenary talks at the 11th Annual International Workshop on HIV and Aging, held virtually from September 30, 2020 to October 2, 2020. We will also address the future directions of HIV and aging research, to further assess how the aging process intersects with chronic HIV.

Entities:  

Keywords:  HIV; aging; antiretroviral therapy; clinical outcomes; neuroscience

Mesh:

Year:  2021        PMID: 34405689      PMCID: PMC8817696          DOI: 10.1089/AID.2021.0059

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  152 in total

1.  A position statement on NAFLD/NASH based on the EASL 2009 special conference.

Authors:  Vlad Ratziu; Stefano Bellentani; Helena Cortez-Pinto; Chris Day; Giulio Marchesini
Journal:  J Hepatol       Date:  2010-05-07       Impact factor: 25.083

2.  Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women.

Authors:  A Y McDermott; A Shevitz; T Knox; R Roubenoff; J Kehayias; S Gorbach
Journal:  Am J Clin Nutr       Date:  2001-11       Impact factor: 7.045

3.  Antiretroviral therapy affects the composition of weight loss in HIV infection: implications for clinical nutrition.

Authors:  Bruno S Maia; Ellen S Engelson; Jack Wang; Donald Philip Kotler
Journal:  Clin Nutr       Date:  2005-08-10       Impact factor: 7.324

4.  DUAL-ENERGY X-RAY ABSORPTIOMETRY AND CALCULATED FRAX RISK SCORES MAY UNDERESTIMATE OSTEOPOROTIC FRACTURE RISK IN VITAMIN D-DEFICIENT VETERANS WITH HIV INFECTION.

Authors:  Kelly I Stephens; Leon Rubinsztain; John Payan; Chris Rentsch; David Rimland; Vin Tangpricha
Journal:  Endocr Pract       Date:  2015-12-18       Impact factor: 3.443

Review 5.  Clinical pharmacokinetics of antiretroviral drugs in older persons.

Authors:  John C Schoen; Kristine M Erlandson; Peter L Anderson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-03-20       Impact factor: 4.481

6.  Antiretroviral Therapy Adherence Interruptions Are Associated With Systemic Inflammation Among Ugandans Who Achieved Viral Suppression.

Authors:  Nicholas Musinguzi; Jose Castillo-Mancilla; Mary Morrow; Helen Byakwaga; Samantha Mawhinney; Tricia H Burdo; Yap Boum; Conrad Muzoora; Bosco M Bwana; Mark J Siedner; Jeffrey N Martin; Peter W Hunt; David R Bangsberg; Jessica E Haberer
Journal:  J Acquir Immune Defic Syndr       Date:  2019-12-01       Impact factor: 3.731

7.  Small-vessel vascular disease in human immunodeficiency virus infection: the Hawaii aging with HIV cohort study.

Authors:  Aaron McMurtray; Beau Nakamoto; Cecelia Shikuma; Victor Valcour
Journal:  Cerebrovasc Dis       Date:  2007-06-28       Impact factor: 2.762

8.  Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis.

Authors:  Raphael Mohr; Christoph Boesecke; Leona Dold; Robert Schierwagen; Carolynne Schwarze-Zander; Jan-Christian Wasmuth; Insa Weisensee; Jürgen Kurt Rockstroh; Jonel Trebicka
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

9.  2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.

Authors:  L Ryom; A Cotter; R De Miguel; C Béguelin; D Podlekareva; J R Arribas; C Marzolini; Pgm Mallon; A Rauch; O Kirk; J M Molina; G Guaraldi; A Winston; S Bhagani; P Cinque; J D Kowalska; S Collins; M Battegay
Journal:  HIV Med       Date:  2020-09-03       Impact factor: 3.180

10.  British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015.

Authors:  Duncan Churchill; Laura Waters; Nadia Ahmed; Brian Angus; Marta Boffito; Mark Bower; David Dunn; Simon Edwards; Carol Emerson; Sarah Fidler; Martin Fisher; Rob Horne; Saye Khoo; Clifford Leen; Nicola Mackie; Neal Marshall; Fernando Monteiro; Mark Nelson; Chloe Orkin; Adrian Palfreeman; Sarah Pett; Andrew Phillips; Frank Post; Anton Pozniak; Iain Reeves; Caroline Sabin; Roy Trevelion; John Walsh; Ed Wilkins; Ian Williams; Alan Winston
Journal:  HIV Med       Date:  2016-08       Impact factor: 3.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.